Play­ing catch-up, Eli Lil­ly is hus­tling pos­i­tive PhI­II CGRP mi­graine da­ta to the FDA as late-stage ri­val­ry heats up

Eli Lil­ly is hus­tling up a bi­o­log­ics ap­pli­ca­tion for its close­ly-watched mi­graine drug gal­canezum­ab af­ter post­ing some re­mark­ably con­sis­tent and pos­i­tive late-stage da­ta from three Phase III stud­ies.

The top-line da­ta from the Lil­ly $LLY study demon­strat­ed that the 120 and 240 mg dos­es re­duced the av­er­age num­ber of mi­graine days by 4.3 to 4.8 days and 4.2 to 4.6 days a month. The place­bo arm had a 2.3 to 2.8 day month­ly drop in mi­graine days, on av­er­age, leav­ing the drug with a con­sis­tent two-day ad­van­tage that will like­ly do fair­ly well in the mar­ket­ing bat­tle to come as Te­va, Alder and the pow­er­house duo of No­var­tis $NVS and Am­gen $AMGN hus­tle their com­pet­ing CGRP drugs to the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.